Globus Medical Reports Fourth-Quarter and Full-Year 2025 Results

Globus Medical

AUDUBON, PA — Globus Medical Inc. (NYSE: GMED) reported fourth-quarter net sales of $826.4 million and full-year 2025 net sales of $2.94 billion, reflecting double-digit revenue growth and higher earnings compared with 2024.

For the fourth quarter ended December 31, 2025, worldwide net sales increased 25.7% year over year, or 24.7% on a constant currency basis. U.S. net sales rose 27.5%, while international net sales increased 19.0% as reported and 14.2% on a constant currency basis.

Base business net sales, excluding Nevro, were $726.7 million in the quarter, up 10.6% year over year.

GAAP net income for the quarter was $140.6 million, up 430.4% from the prior-year period. GAAP diluted earnings per share were $1.03, compared with $0.19 a year earlier. Non-GAAP diluted EPS was $1.28, up 52.1% from $0.84 in the fourth quarter of 2024.

READ:  Radial Launches Commerce Solutions for Payments and Fraud

For the full year, worldwide net sales increased 16.7% to $2.94 billion. U.S. net sales rose 18.4%, while international net sales increased 10.0% as reported and 7.8% on a constant currency basis.

Full-year GAAP net income was $537.9 million. GAAP diluted EPS was $3.92, up 425.4% from 2024. Non-GAAP diluted EPS was $3.98, an increase of 30.8%.

The company said the increase in quarterly net income was primarily driven by $169.1 million in higher sales, including $99.7 million contributed by the acquisition of Nevro.

READ:  FDA Approves Harmony’s WAKIX for Pediatric Cataplexy

“Our fourth quarter and full-year results underscore the strength of our organization and the significant value being created through the successful integration of NuVasive and Nevro,” Chief Financial Officer Kyle Kline said in a statement.

President and Chief Executive Officer Keith Pfeil said the company plans to focus in 2026 on scaling growth and operating leverage, including launching new products and expanding its sales force.

Globus Medical reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP diluted EPS guidance to a range of $4.40 to $4.50, from a prior range of $4.30 to $4.40.

READ:  EPAM Systems Reports Fourth Quarter and Full-Year 2025 Results

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.